Why the study?
The study investigated the occurrence of no-reflow during PCI for saphenous vein grafts and its relationship with the systemic immune-inflammation index.
Does a high systemic immune-inflammation index predict no-reflow in patients with NSTE-ACS undergoing PCI for saphenous vein grafts?
Does a high systemic immune-inflammation index predict no-reflow in patients with NSTE-ACS undergoing PCI for saphenous vein grafts?
Answers are grounded in this paper and cite their sources.
A higher systemic immune-inflammation index is associated with an increased risk of no-reflow during PCI for saphenous vein grafts in patients with NSTE-ACS.
Objective: In this study, we investigated the occurrence of no-reflow (NR) in percutaneous coronary intervention (PCI) for saphenous vein grafts (SVGs) and its relationship with a new systemic immune-inflammation index (SII) that determines inflammation. Methods: We studied 303 patients with acute coronary syndrome without ST elevation who underwent PCI for SVG disease. Results: NR formation during SVG PCI was significantly higher in patients with high SII (p < 0.001). NR occurrence was 12.8% when SII was ≤548 and 41.9% when SII was >548. Conclusion: Our study is the first to investigate SII as the state of inflammation and its effect on the SVG PCI. Patients with higher SII have a higher risk of NR during an SVG for PCI.
No takes yet. Share an insight, caveat, or question.
Demirci et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: